Brain cancer vaccine - Northwest Biotherapeutics

Drug Profile

Brain cancer vaccine - Northwest Biotherapeutics

Alternative Names: DCVax-Brain; DCVax-Brain personalised immune therapy - Northwest Biotherapeutics; DCVax-L; DCVax-L (Glioblastoma)

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwest Biotherapeutics
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma

Most Recent Events

  • 06 Feb 2017 US FDA lifts partial clinical hold on recruitment in phase III trial for Glioblastoma
  • 08 Dec 2016 Northwest Biotherapeutics completes enrolment early in its phase III trial for Glioblastoma in USA, Canada, Germany and United Kingdom (NCT00045968)
  • 18 Aug 2015 Phase-III development in Glioblastoma (Newly diagnosed) is ongoing in USA, Canada, United Kingdom and Germany (NCT00045968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top